Janney Upgrades Amicus Therapeutics (FOLD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Leerink Swann Upgrades Amicus Therapeutics (FOLD) to Outperform
July 1, 2014 6:55 AM EDTLeerink Swann upgraded Amicus Therapeutics (NASDAQ: FOLD) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $3.34 yesterday.
... MoreJPMorgan Upgrades Amicus Therapeutics (FOLD) to Overweight
June 30, 2014 12:32 PM EDTAmid today's news, JPMorgan analyst Anupam Rama upgraded Amicus Therapeutics (NASDAQ: FOLD) from Neutral to Overweight with a price target of $7.00 given study 012 high probability of sucess and favorable risk/reward.
Rama said, "After literature review and speaking to multiple physicians, we... More
Amicus Therapeutics (FOLD) Moves Higher on Volume
June 30, 2014 11:52 AM EDTAmicus Therapeutics (NASDAQ: FOLD) moving to the highs of the session on volume. Shares up 28.7%.
This morning, the company provided... More
Amicus Therapeutics (FOLD) Updates on Migalastat Phase 3; Top-Line Data Expected in Q314
June 30, 2014 7:06 AM EDTAmicus Therapeutics (Nasdaq: FOLD) has provided updates and detailed the statistical analysis plan for its second Phase 3 study (Study 012) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations. The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations.
Study 012 is the first clinical study to compare oral migalastat to standard-of-care enzyme replacement therapies (ERTs)... More
